Summary
The Central Drugs Standard Control Organisation has approved Qdenga, India's first dengue vaccine, developed by Japan's Takeda and already licensed in over 40 countries with WHO prequalification. The tetravalent shot, unlike its predecessor Dengvaxia, can be given without screening for prior dengue infection, but requires two doses three months apart and protects unevenly across the four dengue serotypes.
Protection is strongest against DENV-2 and weaker and more uncertain against DENV-3, a strain whose prevalence is rising in India, raising concerns for the highly mobile migrant workforce and dense urban slums least likely to complete both doses affordably.
WHY IN NEWS FOR UPSC & STATE PCS
India's dengue-vaccine milestone has arrived alongside two unresolved problems: Takeda's tiered global pricing may put Qdenga out of reach for slum residents with the worst Aedes exposure and its two-dose, three-month schedule is hardest to complete for the migrant workers who move between those exact high-risk settlements.
Standard News
One Dose Is Not Half Protection
- Sometimes It's Worse Than None Picture a migrant construction worker who gets his first Qdenga shot at a public health camp in June, then moves for work before the second dose window in September arrives. He isn't half-protected. Depending on which dengue serotype finds him next, he may be barely protected at all - and he has no way of knowing that.
THE MANUFACTURER'S CASE, TAKEN SERIOUSLY
Building a vaccine against four serotypes at once is genuinely harder than building one against a single virus. Antibody-dependent enhancement means a poorly designed shot can make a second infection worse, as Dengvaxia's 2017 Philippines crisis proved. Takeda's caution and its price, reflect real R&D cost that a single-price global rollout likely couldn't recover. Tiered pricing is how global health access usually works
- it lets wealthier markets subsidize supply to poorer ones over time, rather than nobody getting the vaccine at all.
THE COST THAT PRICING TIERS DON'T SOLVE
WHO ACTUALLY FACES THIS RISK
It isn't a random slice of the population. It's people in dense slums with poor drainage - Aedes breeds in exactly the standing water those settlements can't drain - who are also least able to absorb Takeda's price and migrant workers whose mobility makes a fixed three-month return appointment the least reliable part of their week.
THE RESOLUTION
The easy answer would be to treat this as a rollout success with a pricing footnote to fix later. It isn't that. Vaccinating people into a partially-protected, DENV-3-exposed gap and calling it public health progress is a real harm, not a delay. The government should negotiate a lower tiered price specifically for below-poverty-line and migrant-registered populations and pair every first dose with a portable, transferable second-dose voucher usable at any public facility nationwide
- accepting the administrative cost of building that system as the real price of not leaving dose-one recipients worse off than if the vaccine had never reached them.
Quick Facts
Qdenga is a live-attenuated tetravalent vaccine requiring two doses three months apart. It is licensed in over 40 countries and holds WHO prequalification. The CDSCO approval falls under the Drugs and Cosmetics Act, 1940, administered by the Ministry of Health and Family Welfare.
Connect the dots for your UPSC preparation.
Standard news covers the event. Log in to read our comprehensive analysis and uncover the hidden constitutional, structural, and ethical dimensions of this topic:
The full utilitarian-versus-precautionary framework applied to who should get scarce, subsidized doses first
A District Health Officer case study modeled on this exact serotype-timing gap, with a defended resolution
How the 2017 Dengvaxia crisis in the Philippines maps onto India's current rollout risk, point by point
The specific administrative fix - portable dose-two vouchers - worked through against real migrant-mobility patterns
Included in this analysis
Join thousands of aspirants analyzing the news deeply.
Log In to Read Full ArticleDon't have an account? Sign up for free